上海君实生物医药科技股份有限公司 关于持股 5%以上股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露日，上海檀英投资合伙企业（有限合伙）（以下简称"上海 檀英"）持有上海君实生物医药科技股份有限公司（以下简称"公司"或"君实 生物"）股份 71,459,326 股，股份性质为 A 股，占公司总股本的 6.9602%。上述 股份为公司首次公开发行股票并在上海证券交易所科创板上市（以下简称"IPO"） 前取得的股份，且已于 2021 年 7 月 15 日起解除限售并上市流通。 减持计划的主要内容 上海檀英长期看好公司的发展，因基金期限与流动性资金安排原因，计划通 过大宗交易的方式减持其持有的公司股份数量不超过 20,533,797 股，减持比例不 超过公司总股本的 2%。上海檀英为在中国证券投资基金业协会备案的私募基金， 已成功申请适用《上市公司创业投资基金股东减持股份的特别规定》和《上海证 券交易所上市公司创业投资基金股东减持股份实施细则 ...

来源：新浪证券-红岸工作室 君实生物8月15日发布公告，持股5%以上股东上海檀英投资合伙企业（有限合伙）（以下简称"上海檀 英"）因基金期限与流动性资金安排，计划通过大宗交易方式减持公司股份。 上海檀英持股情况 截至公告披露日，上海檀英持有君实生物A股股份7145.93万股，占公司总股本的6.9602%。该部分股份 为公司首次公开发行股票并在科创板上市（IPO）前取得，已于2021年7月15日起解除限售并上市流 通。 上海檀英的执行事务合伙人为上海正心谷投资管理有限公司，实际控制人为林利军先生。其与Loyal Valley Capital Advantage Fund II LP、LVC Renaissance Fund LP为一致行动人，三者合计持有君实生物 8721.80万股，占总股本的8.4951% 。 过去12个月内，上海檀英及上海檀正投资合伙企业曾于2024年10月23日至11月12日期间，减持739.27万 股，减持比例0.75%，减持价格区间为29.54 - 34.04元/股 。 股东名称持有数量（股）持有比例一致行动关系形成原因上海檀英71,459,3266.9602%上海檀英的执行 事务合伙 ...

格隆汇8月14日丨君实生物(688180.SH)公布，上海檀英长期看好公司的发展，因基金期限与流动性资金 安排原因，计划通过大宗交易的方式减持其持有的公司股份数量不超过2053.38万股，减持比例不超过 公司总股本的2%。拟通过大宗交易方式减持的，在任意连续60日内减持股份的总数不超过公司总股本 的2%，自本公告披露之日起15个交易日后的三个月内进行。上述股份的减持价格按市场价格确定。 ...

格隆汇8月14日｜君实生物(688180.SH)公告称，公司持股5%以上股东上海檀英计划通过大宗交易方式 减持其持有的公司股份数量不超过2053.38万股，减持比例不超过公司总股本的2%。相关股份均为IPO 前取得。 ...

Core Viewpoint - Junshi Biosciences aims to establish itself as a global innovative pharmaceutical company with a complete industry chain capability from drug discovery to commercialization, focusing on quality and innovation [2][3]. Company Overview - Junshi Biosciences, founded on December 27, 2012, and listed on July 15, 2020, specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7]. - The company's main revenue sources include drug sales (84.18%), technology licensing (12.08%), and other income (3.73%) [7]. Product Development - The company has developed a promising drug portfolio, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2]. - Toripalimab is also the first innovative biologic drug developed and produced in China to receive FDA approval, with approvals in multiple regions including the U.S., EU, and Australia [2]. - Junshi's self-developed Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, currently undergoing two Phase III registration clinical trials [2]. Vaccine Development - The company is collaborating with various research institutions and universities to develop vaccine-related products, including monkeypox and Zika vaccines, which are currently in preclinical development [3]. - On October 27, 2023, Junshi announced a partnership with Peking University and other institutions to jointly develop a recombinant protein vaccine for monkeypox [3]. Financial Performance - For the period from January to March 2025, Junshi Biosciences reported revenue of 5.01 billion yuan, a year-on-year increase of 31.46%, while the net profit attributable to shareholders was -2.35 billion yuan, reflecting a year-on-year increase of 17.01% [8]. Market Position - As of March 31, 2025, Junshi Biosciences had 29,400 shareholders, with an average of 25,987 circulating shares per person, indicating a slight decrease in share distribution [8]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the biopharmaceuticals category, and is involved in various concepts including monkeypox, precision medicine, and mid-cap stocks [8].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 上海君實生物醫藥科技股份有限公司（「本公司」及其附屬公司「本集團」）董事會 （「董事會」）茲通告謹定於2025年8月26日（星期二）舉行董事會會議，以考慮及通 過本集團截至2025年6月30日止六個月的中期業績，以及處理其他事項。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年8月14日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、楊悅博士、酈仲賢先生及魯琨 女士。 * 僅供識別之用 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 董事會召開日期 ...

格隆汇8月14日丨君实生物(01877.HK)宣布，谨定于2025年8月26日（星期二）举行董事会会议，以考虑 及通过本集团截至2025年6月30日止六个月的中期业绩，以及处理其他事项。 ...

上海君實生物醫藥科技股份有限公司（「本公司」及其附屬公司「本集團」）董事會 （「董事會」）茲通告謹定於2025年8月26日（星期二）舉行董事會會議，以考慮及通 過本集團截至2025年6月30日止六個月的中期業績，以及處理其他事項。 SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 董事會召開日期 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 承董事會命 上海君實生物醫藥科技股份有限公司 熊俊先生 主席 中國，上海，2025年8月14日 於本公告日期，本公司董事會包括執行董事熊俊先生、李寧博士、鄒建軍博士、 李聰先生、張卓兵先生、姚盛博士、王剛博士及李鑫博士；非執行董事湯毅先 生；以及獨立非執行董事張淳先生、馮曉源博士、楊悅博士、酈仲賢先生及魯琨 女士。 * 僅供識別之用 ...

Core Viewpoint - Junshi Biosciences is positioned as a comprehensive innovative pharmaceutical company with capabilities spanning drug discovery, clinical research, large-scale production, and commercialization, aiming for a global footprint while being rooted in China [2] Group 1: Company Overview - Junshi Biosciences was established on December 27, 2012, and went public on July 15, 2020, focusing on the research and commercialization of monoclonal antibodies and therapeutic proteins [7] - The company's main revenue sources include drug sales (84.18%), technology licensing (12.08%), and other income (3.73%) [7] - As of March 31, 2025, Junshi Biosciences reported a revenue of 5.01 billion yuan, a year-on-year increase of 31.46%, and a net profit attributable to shareholders of -235 million yuan, a year-on-year increase of 17.01% [8] Group 2: Product Pipeline and Innovations - The company has developed a robust product pipeline, including the first domestically approved PD-1 monoclonal antibody, Toripalimab, which has received approval for 11 indications in mainland China and is also approved in multiple countries including the US and EU [2] - Junshi Biosciences is advancing its first-in-human anti-tumor BTLA monoclonal antibody, Tifcemalimab, which is currently undergoing two Phase III clinical trials [2] - The company is also collaborating with various research institutions to develop vaccines, including a monkeypox vaccine, which is in the preclinical development stage [3] Group 3: Market Performance - On August 13, Junshi Biosciences' stock rose by 5.03%, with a trading volume of 1.025 billion yuan and a market capitalization of 44.62 billion yuan [1] - The stock has shown a net inflow of 48.8 million yuan from major investors, indicating a lack of clear trend in major holdings [5] - The average trading cost of the stock is 36.29 yuan, with the current price approaching a resistance level of 44.00 yuan, suggesting potential for upward movement if this level is breached [6]

Company Overview - Junshi Biosciences has seen a stock price increase of 54.45% year-to-date, with a 2.25% rise in the last five trading days, 8.87% in the last 20 days, and 42.70% in the last 60 days [2] - The company specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs, with 84.18% of its revenue coming from drug sales, 12.08% from technology licensing, and 3.73% from other sources [2] - As of March 31, 2025, Junshi Biosciences reported a revenue of 5.01 billion yuan, a year-on-year increase of 31.46%, while the net profit attributable to shareholders was -2.35 billion yuan, reflecting a year-on-year growth of 17.01% [2] Market Performance - As of August 13, Junshi Biosciences' stock was trading at 42.21 yuan per share, with a market capitalization of 43.337 billion yuan [1] - The stock experienced a net inflow of 8.2718 million yuan from main funds, with significant buying and selling activity from large orders [1] Shareholder Structure - As of March 31, 2025, the top ten circulating shareholders included notable ETFs, with 华夏上证科创板50成份ETF holding 30.2534 million shares, a decrease of 5.0506 million shares from the previous period [3] - 易方达上证科创板50ETF held 21.5833 million shares, also showing a decrease of 0.8692 million shares [3] - 香港中央结算有限公司 increased its holdings to 14.9956 million shares, an increase of 0.15278 million shares [3]